About 232,000 new cases of melanoma are diagnosed worldwide each year, according to the WHO. More recent research led to the development of new therapies for metastatic melanoma such as targeted therapy (inhibition of BRAF and/or MEK genes) and checkpoint inhibitor immunotherapy. Both therapies prolong progression-free and overall survival compared with chemotherapy. The aim of this research was to compare combined targed therapy and checkpoint inhibitor immunotherapy costeffectiveness, through cost-effectiveness analysis (CEA) and budget impact analysis (BIA) for the Italian context over a period of three years.
